Risk factor modification: rationale for management of dyslipidemia

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Clinical trials demonstrate the efficacy of cholesterol-lowering therapies in preventing coronary artery disease (CAD).
• Established evidence since the 1980s supports lipid-lowering as a risk-reduction strategy.
• 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, offer improved patient compliance and fewer side effects.

Purpose of the Study:

• To highlight the established efficacy of cholesterol lowering in CAD prevention.
• To underscore the benefits of statins as a preferred lipid-lowering therapy.
• To address the gap in physician adherence to prescribing lipid-lowering treatments.

Main Methods:

• Review of key clinical trials (e.g., 4S, WOSCOPS, CARE) demonstrating cholesterol-lowering benefits.
• Analysis of the impact of low-density lipoprotein (LDL) cholesterol reduction on CAD risk.
• Comparison of statins with other lipid-lowering agents regarding efficacy and patient compliance.

Main Results:

• Numerous studies confirm that lowering elevated LDL cholesterol significantly reduces CAD risk.
• Statins have proven effective and well-tolerated, leading to better patient compliance.
• Despite clear benefits, a significant number of eligible patients are not receiving necessary lipid-lowering therapy.

Conclusions:

• Cholesterol lowering, particularly with statins, is a proven and effective strategy for primary and secondary CAD prevention.
• Physicians must improve the uptake of evidence-based lipid-lowering therapies to mitigate CAD risk in eligible patient populations.